Leids Universitair Medisch Centrum (LUMC)
Responsive
Leiden, The Netherlands
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial studies the immune system response to pneumococcal vaccines in different groups of people, including young healthy adults, older adults, and people living with HIV. The study will examine how two different types of pneumococcal vaccines - Prevenar 20 and Pneumovax 23 - affect the formation of special structures in lymph nodes called germinal centers, which are important for immune system function.
The study involves taking small samples from lymph nodes and blood to analyze how the immune system responds to vaccination. Participants will receive a single dose of one of the pneumococcal vaccines through an intramuscular injection. The researchers will monitor the immune response for up to 6 months after vaccination by collecting blood samples and small amounts of saliva.
The research aims to understand how factors like age and HIV infection influence the body's response to different types of vaccines. This knowledge could help improve vaccination strategies for different groups of people. The study will also look at how lifestyle factors such as diet, exercise, and smoking might affect the immune response to vaccination.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
15 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Leiden, The Netherlands
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
A viral infection that affects the immune system by targeting CD4+ T cells, which are crucial for fighting off infections. The virus gradually weakens the body's natural defenses by reducing the number of these important immune cells. HIV infection progresses through several stages, during which the virus continues to multiply and affect more immune cells. The condition affects the body's ability to respond effectively to various pathogens and can make people more susceptible to other infections. Over time, without intervention, the virus leads to a progressive decline in immune function. The infection can be transmitted through specific bodily fluids, including blood, breast milk, and during sexual contact.
A bacterial infection caused by Streptococcus pneumoniae that can affect various parts of the body. The bacteria can colonize the upper respiratory tract and potentially spread to other areas. The infection commonly begins in the sinuses or lungs but can also affect other body parts. The bacteria can be present in the body without causing illness, a state known as colonization. The infection is more common in people with weakened immune systems and can spread between people through respiratory droplets.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.